RE:RE:The competition had been launched! Where's Aristotle???ScienceFirst wrote: Competition? lollll
Competition is not an issue. There are no monopole in life. So the pie will be big enough for those that have a liquid biopsy platform and it happens that we are among the few to have one.
But what's interesting with competition is the market valuation that they set.
- Galleri bought back GRAIL for 8B$ and their accuracy numbers are lower than ours so far. And before having been bought back by Galleri, GRAIL went through 4 rounds of private Serie A, B, C, D financings totaling 1.9G$. It's all well documented.
- EXAS acquired one platform for 2.8B$ while the EXAS CEO was honest enough to say that they still have huge work to do before reaching full potential. It's also all well documented.
In the meantime, because it's a new market/new technology, we know that will come a time where there will be a bidding war for takeovers as some big players will want to enter this new field, given the obvious advantages of liquid biopsies versus tissue biopsies. And we will be center stage.
So competition is more than welcome, in order to create a new market, and so, a bidding war for takeovers. Building a network of clinics with large healthcare groups, we will soon have volume in terms of tests.
And I'm not even mentioning that we have a pity valuation of 37M$, no valuation since pre-COVID-19, while we're now making profits and that we're not only a COVID-19 company. In fact, SONA Nanotech, which saw its share price tumble from 15$ to 0.75$ after rejections by FDA and HC concerning its sole (COVID-19) technology, has a 35% higher valuation (47M$) than us (35M$)!
So really, who's afraid of competition, apart maybe Olteanu007? lolll
We can only go up from here. And it's gonna start with the conf. call once this pp is close.
SZLS managment has executed very well regarding the COVID-19 opportunity. It has proven that it was capable of closing deals with more than 50 different groups, no matter their locations. And it seems they've been able to redo the coup with Aristotle, again with diversified groups (clinics, large healthcare groups, etc ...). That bodes well for Aristotle.
Yes, this is akin to arguing that GM has to be the only automaker if they are to survive!! Meanwhile Toyota, Honda, Ford, Chrysler etc. etc. make a bit more than a decent living having a relatively small market percentage - really a silly and childish notion to have to refute. Bashers like Oltean just sphew this info out there without using the thought process most of us have. Its like firing darts at a board - eventually one hits and sticks and that 5% success rate, while being a disappointment to the rest of us, nonetheless meets his reduced expectations.